Cspc Megalith Biopharmaceutical Co.,ltd.

This study tests a new mRNA vaccine (SYS6017) to prevent shingles, a painful rash caused by the chickenpox virus. The trial will include 800 healthy adults aged 40 and older. Researchers will compare the new vaccine against a placebo and an existing shingles vaccine to see how we…

This study tests a new drug called SYS6010 against standard chemotherapy for people with advanced or returning esophageal cancer that has not responded to at least one prior treatment. About 436 adults will be randomly assigned to receive either SYS6010 or a standard chemo drug. …

This early-stage study tests a new drug called SYS6051 in 114 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. Participants will receive the drug and …

This phase 3 trial tests a new drug called SYS6002 against standard chemotherapy in about 406 people with advanced bladder cancer that has not responded to platinum chemotherapy and immunotherapy. The main goal is to see if SYS6002 helps people live longer. The study is not yet r…

This study tests a new combination of drugs (SYS6010 and SG001) with or without chemotherapy as a first treatment for people with advanced or metastatic esophageal squamous cell carcinoma. About 737 adults aged 18-75 who have not had prior treatment for advanced disease will part…

This study tests whether adding a new drug (SYS6010) to the standard targeted therapy (osimertinib) before surgery can shrink tumors more effectively in people with a specific type of lung cancer (EGFR-mutant non-small cell lung cancer). About 120 adults with stage II to IIIB dis…

This study tests whether adding a new drug, SYS6010, to the standard treatment osimertinib can help people with a certain type of advanced lung cancer (EGFR-mutant NSCLC) live longer without their cancer growing. About 680 adults aged 18-75 will be split into two groups: one gets…

This study tests a new drug called SYS6010 against a standard chemotherapy (docetaxel) in people with a certain type of advanced lung cancer (non-squamous non-small cell) that no longer responds to standard treatments. About 506 adults will be randomly assigned to receive either …

This study compares a new drug called SYS6002 to the current standard drug PADCEV in people with advanced bladder cancer that has worsened after prior treatments. About 100 adults aged 18-80 will be enrolled to see which drug works better and has fewer side effects. The trial has…

This phase 3 trial tests a new drug called SYS6002 against standard chemotherapy for people with advanced cervical cancer that has returned or spread after prior treatments. About 412 adults aged 18-75 will be randomly assigned to receive either SYS6002 or a chemotherapy chosen b…

This study tests a new drug called SYS6010 against standard chemotherapy for people with a specific type of advanced breast cancer (HER2-negative, EGFR-positive) that has come back or spread. About 400 adults aged 18-75 who have already tried 1-2 chemotherapy treatments will be r…